Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of AK129 alone or with AK117 in relapsed or refractory classical Hodgkin lymphoma after PD-1/PD-L1 inhibitor failure
CTR20243116Phase 2Active
- Sponsor
- Akeso, Inc.
- Start
- Jan 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of AK129, ligufalimab in classical Hodgkin lymphoma (cHL), sponsored by Akeso, Inc.. Started Jan 2025; status: active.
02
Drugs
AK129ligufalimab
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on CTR20243116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243116.